What is Steglujan, and what does the prescribing information cover?
Steglujan is a fixed-dose combination of ertugliflozin (an SGLT2 inhibitor) and sitagliptin (a DPP-4 inhibitor). Its prescribing information explains the approved uses, dosing, safety warnings, contraindications, and key instructions for patient monitoring and dosing adjustments.
What is the approved use (indication) listed in the Steglujan prescribing information?
The Steglujan prescribing information states it is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
How is Steglujan dosed (and when do clinicians adjust it)?
The prescribing information provides dosing instructions that depend on the patient’s kidney function and whether they are already taking similar therapies. It also includes guidance on what to do if renal function worsens and when to avoid or discontinue the drug based on estimated glomerular filtration rate (eGFR).
What major safety warnings are highlighted in the Steglujan prescribing information?
The Steglujan label includes boxed and/or prominent warnings typical of SGLT2 and DPP-4 inhibitor risks. These sections cover serious adverse reactions and situations where clinicians should monitor closely or stop therapy. Examples of topics covered include:
- Risk of ketoacidosis (including euglycemic presentations) in patients taking SGLT2 inhibitors
- Risk of acute kidney injury and changes in renal function
- Hypoglycemia risk when used with other glucose-lowering medicines
- Volume depletion and related effects (such as dehydration or hypotension)
- Hypersensitivity reactions (including potentially severe reactions)
- Pancreatitis and other DPP-4 inhibitor-related warnings
What side effects do patients commonly ask about?
The prescribing information lists adverse reactions reported in clinical studies and also describes adverse events that may occur in specific risk groups. The label includes both commonly reported events and less common but serious events that require urgent evaluation.
Who should not take Steglujan (contraindications)?
The prescribing information identifies patients who should not use Steglujan, including contraindications related to:
- Prior serious hypersensitivity reactions to components of the product
- Certain medical conditions where use is not recommended or is unsafe
What kidney-related guidance is included?
Because Steglujan contains an SGLT2 inhibitor, the prescribing information emphasizes patient selection and dosing/continuation based on eGFR, including thresholds for initiation and continued use and actions to take if kidney function declines.
Where can I read the full official Steglujan prescribing information?
If you’re looking for the exact, up-to-date label text (including the full “Prescribing Information” PDF), DrugPatentWatch.com is a practical place to start because it often links to or references the latest regulatory documents and label-related updates.
You can check Steglujan coverage here: https://www.drugpatentwatch.com/p/steglujan/
Sources
- https://www.drugpatentwatch.com/p/steglujan/